A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia

• Published in: The Clinical journal of pain Vol. 25; no. 5; p. 365
• Main Authors: Chappell, Amy S, Littlejohn, Geoffrey, Kajdasz, Daniel K, Scheinberg, Morton, D'Souza, Deborah N, Moldofsky, Harvey
• Format: Journal Article
• Language: English
• Published: United States 01.06.2009
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Comorbidity; Dopamine Uptake Inhibitors - administration & dosage; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions - epidemiology; Duloxetine Hydrochloride; Female; Fibromyalgia - diagnosis; Fibromyalgia - drug therapy; Fibromyalgia - epidemiology; Humans; Internationality; Male; Middle Aged; Pain - diagnosis; Pain - epidemiology; Pain - prevention & control; Pain Measurement - drug effects; Thiophenes - administration & dosage; Treatment Outcome; Young Adult

Evaluate the efficacy and safety of duloxetine at doses up to 120 mg once daily in patients with fibromyalgia. This was a phase 3, 60-week study, which included an 8-week open-label period followed by a 52-week, randomized, double-blind period. Patients received duloxetine 30 mg daily for 1 week and...